Evexia Diagnostics adds GutID microbiome testing to clinician network

Evexia Diagnostics is adding GutID’s high-resolution microbiome test across its national network of functional and integrative medicine clinicians. The partnership gives practitioners access to strain-level microbiome data through Evexia’s platform, aiming to improve insight into unexplained gut issues and chronic disease risk.

Why it matters: - The partnership expands access to more detailed microbiome testing for clinicians who treat gut health and chronic disease. - GutID is positioned as a more advanced option than standard microbiome tests, which often miss strain-level detail and previously uncharacterized bacteria. - Evexia’s network gives GutID a broader route into functional and integrative medicine practices nationwide.

What happened: - Evexia Diagnostics and GutID announced a strategic partnership on July 9, 2026. - GutID will be available across Evexia’s national clinician network. - Functional and integrative medicine practitioners using Evexia can order GutID through the Evexia platform alongside other lab tests. - The announcement came from Washington, Connecticut.

The details: - GutID is powered by Intus Bio’s Titan-1 microbiome platform. - The company describes GutID as the world’s first true microbiome test. - Titan-1 uses patented long-read amplicon technology to produce complete, detailed and accurate microbiome data. - GutID reports previously uncharacterized bacteria that other commercial tests do not capture. - Existing microbiome tests typically rely on short-read sequencing and identify known bacteria only at the genus level. - GutID is designed to help resolve unexplained gut issues, support chronic disease prevention and optimize patient outcomes. - Intus Bio is ISO 9001 certified. - Intus Bio has nearly 40 peer-reviewed publications. - Intus Bio has active research collaborations with leading international institutions focused on microbiome links to cancer and other chronic disease detection and prevention. - Evexia has served licensed and non-licensed to order practitioners since 2007. - Evexia operates a cash-based platform that aggregates access to more than 30 CLIA-certified laboratories. - Evexia says its model is built to reduce administrative burden and provide fast, reliable and affordable diagnostics.

Between the lines: - Evexia is betting that more granular microbiome data will translate into more practical clinical use, not just more sequencing output. - The partnership also suggests growing demand for microbiome tools that fit into mainstream ordering workflows rather than standalone specialty testing. - GutID’s claims of higher resolution and clinical utility are central to the company’s pitch, but those claims are part of a competitive market where validation matters.

What's next: - Evexia practitioners can begin accessing GutID through the Evexia platform. - Intus Bio and Evexia are likely to use the partnership to expand adoption among clinicians focused on personalized and evidence-based care. - More information is available through GutID and Intus Bio.

The bottom line: - Evexia is adding a more detailed microbiome test to its diagnostics menu, and GutID gets immediate distribution into a large practitioner network.